Comparison of the effect of low dose Megestrol (40 mg) and Medroxyprogesterone 10 mg on the quality of life in menopausal women.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230930059567N1

Enrollment

Registered

2023-11-11

Start date

2023-11-22

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopause symptoms. Menopausal and other perimenopausal disorders

Interventions

Intervention 1: Intervention group: Megestrol Acetate, C24H32O4, 40 milligrams, one tablet per day, for one month, accompanied by a glass of water. Intervention 2: Intervention group : Medroxyprogeste

Eligibility

Sex/Gender

Female

Age

45 Years to 55 Years

Inclusion criteria

Inclusion criteria: Iranian women aged 45 to 55 year?. FSH serum level greater than or equal to 40-20 mm units per milliliter (pre menopausal) Do not have a physical or mental illness . Do not have addiction or use of hookah cigarettes or alcohol. The person's body mass index should be less than or equal to 29.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Quality of life score in menqol questionnaire. Timepoint: Measuring the quality of life during the study and 1 month after Megestrol consumption. Method of measurement: Menopausal Women's Quality of Life Questionnaire - Persian version (Menqol).;Quality of life score in menqol questionnaire. Timepoint: Measuring the quality of life during the study and 1 month after Medroxyprogestrone consumption. Method of measurement: Menopausal Women's Quality of Life Questionnaire - Persian version (Menqol).	—

Measure

Time frame

Quality of life score in menqol questionnaire. Timepoint: Measuring the quality of life during the study and 1 month after Megestrol consumption. Method of measurement: Menopausal Women's Quality of Life Questionnaire - Persian version (Menqol).;Quality of life score in menqol questionnaire. Timepoint: Measuring the quality of life during the study and 1 month after Medroxyprogestrone consumption. Method of measurement: Menopausal Women's Quality of Life Questionnaire - Persian version (Menqol).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamira Abdollahi

Karaj University of Medical Sciences

samiraabdollahi66@yahoo.com+98 26 3419 7000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026